Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Levosalbutamol; Levosalbutamol; Prednisolone; Prednisolone; Prednisone; Prednisone; Salbutamol; Salbutamol
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBERTY ASTHMA VENTURE; VENTURE
  • Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

    • Most Recent Events

    • 26 Feb 2024 Results assessing the association between baseline characteristics and OCS reduction in patients with OCS dependent severe asthma , presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 09 Dec 2022 Results (from two studies NCT02528214 and NCT02134028) assessing Long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma published in the Annals of Allergy, Asthma and Immunology
    • 09 Nov 2022 Results of post hoc analysis from TRAVERSE (NCT02134028), and VENTURE (NCT02528214) assessing dupilumab efficacy in patients presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top